Role Of α-Receptor Blockers In Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Meta-Analysis

Objective:To evaluate the efficacy and safety of a-receptor blockers for chronic prostatitis/chronic pelvic pain syndrome.Methods:A fully recursive literature search to March 2010 was conducted in the Cochrane library,PubMed,EMBASE,China National Knowledge Infrastructure,the Chinese Biological Medicine Database,the Chinese Science and Technology Jomual Full-text Database to identify potentially relevant randomized controlled trials,co-mparing a-receptor blockers to placebo or other treatments control in patients with CP/CPPS and with no restrictions of languages.Additional studies were identified through a manual search of the bibliographies of the retrieved articles,recent reviews and monographs.Data mainly including NIH-CPSI,IPSS,PSSI scores were extracted from the treatment arm and the control arm respectively.RevMan4.2 was used for statistical analysis.Results:A total of 13 CP/CPPS treatment random control trials involving 1145 patients were included,of which 7 met the high-quality criteria.Combined analysis showed a statistically significant reduction of total and subtotal NIH-CPSI,IPSS,PSSI in patients. Individual treatment effects were statistically significant more often when treatment was administered for 3 months or longer.There were also valuable results in white blood cells reduction of expressed prostatic secretion.Alpha-receptor blockers did not show benefit in Qmax. The rates of adverse events in the two groups were also similar,without severe incidents reported.Conclusions:The meta-analysis revealed that "softly" effective treatment was available for CP/CPPS,and the treatment duration should be long enough(more than 3 months).More high-quality,randomized,controlled trials are essential to prove the conclusions of this research.